When Jianhong Zhu treated a patient with a chopstick lodged in his brain, not an uncommon injury in the country, the culinary implement ultimately helped repair the damage it had caused.
Pulling out the offending object, the Harvard-trained doctor saw fresh brain tissue and decided to culture it in the laboratory and transplant it into the patient.

It was the start of a breakthrough in treating nerve damage and a sign that China is set to become the leader in the field of stem cell research, a field that could in the future help ailments as diverse as paralysis and incontinence.

Professor Jianhong has treated eight brain-damaged patients with their own cells and has reported remarkable results. The results were compared with brain-damaged patients with no open wounds - who cannot be treated this way because there is no easy way to get the brain cells - to demonstrate that implanting the stem cells increased the movement and response of patients.

The results are not published in any academic journal, which normally produces scepticism about such claims.

But his technique amazed British scientists who visited his lab last September, as part of a Department of Trade and Industry mission to learn about stem cell research in the far east.

In a report to be published today by the ministry, the science taking place in China, Singapore and South Korea is described as world-leading. "They are at, or approaching, the forefront of international stem cell research," stated the report.

Prof Jianhong will discuss his work, along with other Chinese and British scientists at a conference in London today organised by the DTI.
"During our 14-day visit to China, Singapore and South Korea, we encountered some of the best equipped laboratories, most industrious research teams, and most adventurous clinical programmes that any of us had ever experienced," wrote Jack Price of the Institute of Psychiatry, in the DTI report.

The analysis picked up on how Chinese scientists are keener to apply stem cell research to treating patients. A British company, ReNeuron, is one of the nearest to bringing the technique to stroke patients to treat paralysis, but trials are still about a year away.

Britain has been a leader in the area for years, with the US hampered by the Christian right's views on using stem cells from aborted foetuses. However certain states in the US, including California, New Jersey, Illinois and Wisconsin, have now pledged billions to the area in order to catch up.

In Britain scientists are worried that the funding could soon dry up, after the government committed £45m over three years in 2002. Lord Sainsbury, science minister at the DTI, said yesterday that Britain should be motivated to remain the leader in stem cell research by the progress in the East. "Providing funding for research remains at the top of our priorities," he said.

Stephen Minger, a leader in the field at King's College London, says that all Britain needs is a similar amount to the previous commitment from the government, and does not need to match California's $3bn (£1.6bn) grant to keep up. "Most of the money will go into building labs, it won't increase the quality of the work done," he said.

But scientific entrepreneurs such as Sir Christopher Evans and Sir Richard Sykes in Britain are worried enough to start up a "Stem Cell Foundation", a charitable fund to support academics and companies in the area that hopes to raise £100m for British stem cell research.

China has been supported by substantial grants from national and regional government, funding laboratories and luring Chinese scientists in Western labs with competitive salaries. It is now the world's third largest spender on research and development, behind the US and Japan.

Stem cell researchers in the US will reveal this week that the human embryonic cells available to most of them are contaminated and probably useless for medical treatments.

Ajit Varki, professor of medicine at the University of California San Diego, has found the cells lines are tainted with material from animal cells used to help grow them. The human body cannot make the animal molecule, called Neu5Gc, so will recognise the stem cells as foreign and trigger the immune system to attack any implanted in the body.

Prof Varki said: "The human embryonic stem cells remain contaminated by Neu5Gc even when grown in special culture conditions with commercially available serum replacements, apparently because these are also derived from animal products." The results will appear in the journal Nature Medicine.

Dr Minger said most stem cells in Britain would also be affected, but that scientists here always planned to derive new, purer, cell lines for clinical trials. US stem cell experts using government money do not have that luxury because President Bush has restricted research to existing cell lines.

Heather Tomlinson and David Adam
The Guardian